The treatment landscape for relapsed and refractory multiple myeloma (RRMM) has changed dramatically over the past decade, resulting in more therapeutic options for various stages of relapse. In a ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The good news, I guess, is that we have ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with ...

PHILADELPHIA--(BUSINESS WIRE)-- GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and ...

The FDA has granted fast track designation to LBL-034 for patients with relapsed or refractory multiple myeloma. The U.S.

OPN-6602 received orphan drug designation for relapsed or refractory multiple myeloma, highlighting its therapeutic potential. The FDA's orphan drug designation offers benefits like tax credits and ...

The FDA approved subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib (Velcade), ...

Explore the promising results of the REDIRECT trial, combining bispecific therapies for treating relapsed/refractory myeloma ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Sham Mailankody, MBBS, discusses results from the long-term follow-up of CARTITUDE-1 ...

Discussion of patient selection criteria, logistical challenges, toxicity management, and when to favor each immunotherapy approach. The final portion of the discussion focuses on future directions in ...